Table 4 Univariate and multivariate logistic regression for predictors of treatment response (N = 167)
Factors | Unadjusted (Univariate Analysis) | Adjusted* (Multivariate Analysis) | ||
|---|---|---|---|---|
Odds ratio (95% confidence interval) | P-value | Odds ratio (95% confidence interval) | P-value | |
Baseline inflammatory marker level | ||||
ESR status (Cut-off level: High vs. Low-normal) | ||||
• Total N = 123 | 1.54 (0.76–3.14) | 0.234 | 1.63 (0.75–3.55) | 0.217 |
• Exclude discordant with CRP *N = 95 | 2.35 (1.02–5.39) | 0.045 | 2.78 (1.06–7.29) | 0.038 |
CRP status (Cut-off level: High vs. Low-normal) | ||||
• Total N = 148 | 2.38 (1.21–4.67) | 0.012 | 2.68 (1.27–5.67) | 0.010 |
• Exclude discordant with ESR *N = 120 | 2.35 (1.11–4.97) | 0.025 | 2.68 (1.17–6.17) | 0.020 |
Age | 1.01 (0.98–1.03) | 0.660 | 1.02 (0.99–1.05) | 0.133 |
Gender | 0.91 (0.49–1.68) | 0.757 | 1.03 (0.53–1.99) | 0.934 |
Duration of anti-inflammatory treatment (at response evaluation) | 0.99 (0.96–1.01) | 0.240 | 0.98 (0.96–1.01) | 0.190 |
Antifibrotics in combination with anti-inflammatory treatment | 1.57 (0.60–4.14) | 0.357 | 1.25 (0.44–3.53) | 0.671 |
Baseline PFT | ||||
FVC (%predicted) *N = 166 | 0.98 (0.96–0.99) | 0.024 | 0.98 (0.96-1.00) | 0.015 |
DLCO (%predicted) *N = 149 | 0.99 (0.98–1.01) | 0.396 | 1.01 (0.97–1.03) | 0.434 |
Progression before initiating treatment | ||||
Meet any of the criteria | 1.48 (0.78–2.80) | 0.227 | 1.21 (0.61–2.41) | 0.588 |
PPF by ATS/ERS/JRS/ALAT 2022 | 0.97 (0.37–1.64) | 0.502 | 0.62 (0.28–1.39) | 0.245 |
PF-ILD by INBUILD criteria | 1.48 (0.78–2.82) | 0.228 | 1.27 (0.63–2.53) | 0.502 |
Baseline HRCT | ||||
• UIP pattern (typical & probable UIP) | 0.52 (0.18–1.49) | 0.225 | 0.43 (0.14–1.32) | 0.139 |
• Indeterminate UIP | 1.47 (0.32–6.79) | 0.619 | 2.26 (0.49–11.43) | 0.323 |
• fNSIP | 2.27 (0.55–9.39) | 0.258 | 2.24 (0.49–10.05) | 0.293 |
Diagnosis | ||||
SARDs related (exclude IPAF, fHP, unclassifiable ILD) | 2.23 (1.19–4.17) | 0.013 | 2.90 (1.45–5.81) | 0.003 |